Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 94 | 1 | 94 | +1 |
| Shares | 27.3M | 11.1K | 30.2M | +2.85M (+10.4%) |
| Value | $230.0M | $94.0K | $334.3M | +$104.4M (+45.4%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 2,414,897 | $26.8M | 0.53% |
| Candriam Luxembourg S.C.A. | 112,035 | $1.24M | 0.01% |
| HRT Financial LP | 52,801 | $585.0K | 0.01% |
| Millennium Management LLC | 50,396 | $558.0K | 0.00% |
| Curi Capital | 45,000 | $499.0K | 0.08% |
| Jane Street Group, LLC | 31,569 | $350.0K | 0.00% |
| Susquehanna International Group, LLP | 23,899 | $265.0K | 0.00% |
| Balyasny Asset Management LLC | 18,532 | $205.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 18,294 | $203.0K | 0.00% |
| Allworth Financial LP | 14,376 | $159.0K | 0.00% |
| Ergoteles LLC | 14,378 | $159.0K | 0.01% |
| Staley Capital Advisers Inc | 10,000 | $111.0K | 0.01% |
| UBS Group AG | 628 | $7.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 367 | $4.00K | 0.00% |
| Wipfli Financial Advisors LLC, | 115 | $1.00K | 0.00% |
| Massmutual Trust Co FSB | 28 | $0 | 0.00% |
| Point72 Hong Kong Ltd | 39 | $0 | 0.00% |
| Ellevest, Inc. | 12 | $0 | 0.00% |
| Parallel Advisors, LLC | 29 | $0 | 0.00% |
Sold out (18)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Janus Henderson Group PLC | 1,092,212 | $9.22M |
| Eventide Asset Management, LLC | 336,223 | $2.84M |
| Western Standard LLC | 109,055 | $920.0K |
| Pura Vida Investments, LLC | 102,328 | $864.0K |
| Walleye Capital LLC | 83,031 | $701.0K |
| Parkman Healthcare Partners LLC | 69,135 | $583.0K |
| Chartwell Investment Partners, LLC | 68,236 | $576.0K |
| Marshall Wace, LLP | 54,769 | $462.0K |
| Two Sigma Investments, LP | 35,304 | $298.0K |
| Summit Rock Advisors, LP | 34,100 | $288.0K |
| Citadel Advisors LLC | 25,012 | $212.0K |
| Venator Management LLC | 25,000 | $211.0K |
| Renaissance Technologies LLC | 24,000 | $203.0K |
| PDT Partners, LLC | 11,922 | $101.0K |
| Federation des caisses Desjardins du Quebec | 600 | $5.06K |
| Aquatic Capital Management LLC | 400 | $3.00K |
| Captrust Financial Advisors | 99 | $1.00K |
| Mirae Asset Global Investments Co., Ltd. | 89,942 | – |
Not filed for Q3 2022 yet (1)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Exane Derivatives | 11,141 | $94.0K |